The exact text we saved

This is the version exactly as it was saved, character for character. The SHA-256 hash below is a 64-character code worked out from that text. Run the same text through SHA-256 and you get the same code; change a single letter and the code comes out completely different. Each version also stores the previous version’s hash, which chains them together so no version can be swapped out quietly.

TRUVACE RECORD VERSION
record: TRV-2026-1173
version: 3
kind: revised
reason: Voice pass: plainer wording and study attribution; no facts or figures changed.
timestamp: 2026-11-05T11:20:08.475330Z
status: published
lens: general
sector: health
headline: AI-Driven precision targeted therapy for EGFR-mutant non-small cell lung cancer: From therapeutic evolution and resistance mechanisms to intelligent decision systems
dek: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision…
gain_title: (none)
problem_title: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup).
trace_subject: (none)
gain_reading: (none)
gain_evidence: (none)
problem_reading: ObjectiveTo critically review the current pharmacologic treatment landscape for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup).
problem_evidence: (none)
quick_read: ObjectiveTo critically review the current drug treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.

Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
limitation: 
tag: Context
key_points: We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks. | Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. | AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
rundown: ObjectiveTo critically review the current drug treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), focusing on clinical pharmacology, therapeutic evolution, and emerging challenges of EGFR-targeted therapies.Data SourcesPeer-reviewed literature in PubMed, Web of Science, and Embase databases (January 2000 to June 2026) was searched using keywords including "EGFR-mutant NSCLC," "EGFR-TKIs," "drug resistance," "artificial intelligence," and "precision oncology." Reference lists and clinical trial registries were also screened.Data SummaryThis review systematically examines clinical misconceptions surrounding EGFR-targeted therapies, focusing on three cognitive biases that undermine precision implementation: overgeneralization of trial efficacy to unselected populations; oversimplified sequencing that ignores clonal selection trade-offs (second-generation TKIs reduce subsequent osimertinib Progression-free survival (PFS) by ∼2 months); and inflated efficacy perceptions for Ex20ins inhibitors (aggregate objective response rate (ORR) masks far-loop responses of only 22%) and MET combinations (true benefit confined to high-expression subgroup). We also critically evaluate artificial intelligence's translational potential in molecular subtyping, resistance prediction, and drug discovery, alongside the data, modeling, and validation barriers limiting its clinical deployment.ConclusionsDespite the expanding therapeutic armamentarium, clinically meaningful precision remains constrained by persistent misconceptions and translational bottlenecks.

Artificial intelligence (AI) offers enabling potential, but its integration requires standardized data infrastructures, dynamic modeling, and prospective validation. AI outputs should currently be interpreted as hypothesis-generating tools, not replacements for clinical judgment.
sources:
- peer_reviewed | Journal of Oncology Pharmacy Practice | https://doi.org/10.1177/10781552261488860 | 2026-09-22
prev: e301b7704f83d30af67e0bb99903bc7abf7b9e2de5bf78291a115a84ac49d393

SHA-256 hash

21c9a595a91735a3b7bcac1b33f9db5b1666f6a97a8871a9a0a771a8978b048f

Previous version’s hash

e301b7704f83d30af67e0bb99903bc7abf7b9e2de5bf78291a115a84ac49d393